AAD: Ivarmacitinib 4 mg, 8 mg Efficacious for Adults With Severe Alopecia Areata
By Elana Gotkine HealthDay Reporter
THURSDAY, March 13, 2025 -- For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses of 4 and 8 mg is efficacious and tolerable, according to a study presented at the annual meeting of the American Academy of Dermatology, held from March 7 to 11 in Orlando, Florida.
Jianzhong Zhang, M.D., of the Peking University People's Hospital in Beijing, and colleagues examined the efficacy and safety of ivarmacitinib in adults with severe AA (≥50 percent scalp hair loss, including alopecia totalis/universalis) in a phase 3 trial. Three hundred thirty patients were randomly assigned to receive either daily oral ivarmacitinib (4 or 8 mg) or placebo for 24 weeks (109, 111, and 110 patients, respectively), followed by a double-blind extension phase of 28 weeks. After 24 weeks, patients receiving placebo were re-randomly assigned to ivarmacitinib 4 or 8 mg.
The researchers found that 34.9, 40.6, and 9.0 percent of those assigned to ivarmacitinib 4 mg, 8 mg, and placebo, respectively, achieved a Severity of Alopecia Tool score ≤20 at week 24. The response rate difference versus placebo was 25.6 and 31.6 percent, respectively, for ivarmacitinib 4 mg and 8 mg. Treatment-emergent adverse events occurred in 77.1, 84.7, and 75.5 percent of those assigned to ivarmacitinib 4 mg, 8 mg, and placebo, respectively, during the placebo-controlled period. No new safety signals emerged. No deaths, thromboembolic events, or major cardiovascular events were reported; one stage III follicular lymphoma case and one thyroid cancer case were reported with ivarmacitinib 4 mg and 8 mg, respectively.
"Ivarmacitinib, at 4-mg and 8-mg doses, demonstrated significant efficacy and tolerability in patients with severe AA," the authors write.
The study was funded by Jiangsu Hengrui Pharmaceuticals, the developer of ivarmacitinib.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted March 2025
Read this next
Low-Dose Doxycycline Effective for Lymphocytic Scarring Alopecias
FRIDAY, March 21, 2025 – Relative to high-dose doxycycline, low-dose doxycycline is comparably effective but more tolerable for lymphocytic scarring alopecias...
American Academy of Dermatology, March 7 to 11
The annual meeting of the American Academy of Dermatology was held from March 7 to 11 in Orlando, Florida, and attracted clinicians, academicians, allied health...
AAD: Baricitinib Efficacious for Hair Regrowth in Teens With Severe Alopecia Areata
TUESDAY, March 18, 2025 -- For adolescents with severe alopecia areata (AA), baricitinib is efficacious for hair regrowth, according to a study presented at the annual meeting of...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.